Keywords
Fondaparinux, Heparin Intolerance, Pregnancy, LMWH, Hypersensitivity, Anticoagulant
Fondaparinux, Heparin Intolerance, Pregnancy, LMWH, Hypersensitivity, Anticoagulant
Low-molecular-weight heparin (LMWH), such as enoxaparin, is the preferred anticoagulant for pregnant women due to its effectiveness, safety, and availability. However, if the pregnant patient experiences an allergy, side effect or intolerance, she should be switched to alternative anticoagulation medication. Unfortunately, in such circumstances, the other anti-coagulation options are limited due to teratogenicity, lack of literature support, or cross-reactivity with LMWH.
Fondaparinux, which is a synthetic polysaccharide inhibitor of activated factor X (FXa), has been reported to be a successful alternative anticoagulant in pregnant patients who develop heparin intolerance, such as hypersensitivity skin reaction, which is frequently seen in pregnant patients1. Although it crosses the placental barrier and results in low measurable anti-factor Xa activity in umbilical-cord blood2, it is considered relatively safe since there are no significant reported unfavorable side effects for the mother or child during pregnancy or the postpartum period.
A 37-year-old Saudi female homemaker (G6P4+1) with a history of hypothyroidism on thyroxin and a history of miscarriage and intrauterine fetal death (IUFD) presented to our thrombosis clinic. She explained to us that this is an important pregnancy for her and that she wished to deliver a healthy baby. Her gynecological history comprised of: preeclampsia during her first pregnancy, resulting in premature labor; fetal distress during her second pregnancy; a third pregnancy resulting in premature labor at 30 weeks; a fourth pregnancy resulting in IUFD at 25 weeks; fetal distress in the 31st week of her fifth pregnancy in 2012; and a sixth pregnancy resulting in IUFD in 2015. Therefore, she was referred to our tertiary care hospital and to our clinic to prevent morbidity and mortality in the current pregnancy. She presented to our clinic in 2016, 11 weeks pregnant, and on physical examination, cardiac and respiratory exams were normal. Abdominal examination showed a gravid uterus. Thrombophilia work up including protein C, protein S, antithrombin III, factor V Leiden mutation, prothrombin gene mutation G20210A, and antiphospholipid antibodies were within normal limits (Table 1).
The patient was started on aspirin 81 mg once daily, and low-molecular-weight-heparin (LMWH) 4000 units via subcu- taneous injection once daily. We explained to the patient the rationale for using heparin was to prevent placental microvascular thrombosis and therefore, prevent placental mediated complications such as preeclampsia and IUFD. This is an internationally recommended evidence-based practice.
Five days later, she developed a severe rash, as depicted in Figures 1A–1D. Hence, LMWH was discontinued, and she was asked to resume taking aspirin 81 mg once daily. She was found to be allergic to LMWH (such as enoxaparin and tinzaparin), resulting in symptoms such as swelling, itching, and erythema, which slowly resolved one week after discontinuation of heparin. One month later, on her scheduled follow-up appointment with us, she no longer had any skin rash or any other hypersensitivity reaction symptoms. We suggested fondaparinux 2.5 mg delivered subcutaneously once daily. We explained to the patient that fondaparinux was an alternative anticoagulant for patients intolerant to heparin, with no reported hypersensitivity reactions or adverse effects on the fetus. She agreed, and hence we discontinued aspirin and started her on fondaparinux. We monitored her health through monthly follow-up clinic visits with regular laboratory tests and ultrasounds in the maternal fetal medicine and thrombosis clinics (Table 1). The ultrasounds had no significant findings, with a single viable fetus and normal growth. She was well with no allergic symptoms or discomfort, and kept taking fondaparinux for five months until her planned induction of labor at 38 weeks gestation with cessation of fondaparinux for 24 hours. She delivered a normal healthy baby and we followed up regularly with the patient for six weeks postpartum (Table 1).
Heparin has always been the anticoagulant of choice to prevent and treat a thrombotic event during pregnancy1. However, its use is limited when adverse reactions such as skin rash (type I hypersensitivity reaction) or heparin-induced thrombocytopenia occurs. Hence, in the setting of heparin intolerance with a high risk of thrombosis, alternative choices for anticoagulation becomes limited.
Current evidence shows that fondaparinux is a safe and effective alternative option in the circumstances, such as seen in our case2–4. For instance, a retrospective study comparing the efficacy of fondaparinux to enoxaparin in terms of pregnancy success rate, gestational age, birth weight, and major bleeding complications concluded that both anticoagulants have comparable results5. In addition, a prospective study evaluating the effect of a prophylactic dose of fondaparinux in pregnant women with a history of venous thromboembolism reported 100% uneventful pregnancies without thromboembolic complications6. However, there is limited experience in the use of fondaparinux in pregnancy, but it has been used in patients with heparin intolerance with no reported adverse effects to the fetus or the mother7.
In concordance with the literature, our patient had an uneventful pregnancy without developing an adverse reaction to fondaparinux. With regards to the long-term safety of fondaparinux, several studies in the literature reported no significant difference in safety profile compared to enoxaparin over a period of therapy ranging between a few weeks to eight months.
On the other hand, umbilical blood sampling showed a detectable level of anti-factor Xa, indicating the passage of fondaparinux to fetal circulation. However, the accumulative level is measured and found to be subtherapeutic, and no study reported any complications during pregnancy or post-partum8.
In conclusion, our case demonstrates that fondaparinux is a safe and effective anticoagulant option in the presence of heparin intolerance.
All data underlying the results are available as part of the article and no additional source data are required.
Written informed consent for publication of their clinical details and clinical images was obtained from the patient.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the background of the case’s history and progression described in sufficient detail?
Partly
Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Partly
Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Partly
Is the case presented with sufficient detail to be useful for other practitioners?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Haemostasis, coagulopathies in placenta mediated complications, Women's Health
Is the background of the case’s history and progression described in sufficient detail?
No
Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Yes
Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
No
Is the case presented with sufficient detail to be useful for other practitioners?
No
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: VTE
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 28 Nov 19 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)